HYBIO(SZ:300199) Zheng Quan Shi Bao Wang·2025-09-25 14:54Core Viewpoint - Han Yu Pharmaceutical plans to raise up to 968 million yuan through a private placement of A-shares, primarily to fund the expansion of its peptide drug production line, the development of Semaglutide, and to supplement working capital [1][2] Group 1: Fund Allocation - The company intends to allocate 495 million yuan for the expansion of the peptide drug production line and green intelligent projects [1] - 98 million yuan is earmarked for the Semaglutide development project, with 25 million yuan for the domestic injectable form and 73 million yuan for the oral form in the U.S. [1] - 280 million yuan will be used to supplement working capital [1] Group 2: Market Opportunity - The global GLP-1 drug market is expected to exceed 33.6 billion dollars in sales by mid-2025, with annual sales projected to surpass 60 billion dollars [1] - Semaglutide and other GLP-1 products are experiencing rapid growth and expanding indications, which will further increase market potential [1][2] Group 3: Business Strategy - The expansion project aims to enhance the company's large-scale production capacity for peptide raw materials, ensuring a continuous supply of raw materials to meet growing market demand [2] - The company aims to accelerate the research and registration process for Semaglutide formulations, enhancing its product diversity and competitiveness in the GLP-1 drug sector [2] Group 4: Financial Performance - In the first half of the year, Han Yu Pharmaceutical achieved a revenue of 549 million yuan, a significant increase of 114.86% year-on-year, and a net profit of 145 million yuan, marking a turnaround from losses [3] - The revenue growth is attributed to the expansion of the company's international formulation business and the approval of Liraglutide injection by the U.S. FDA, which is expected to boost sales [3]